Divi’s Labs could emerge as a key beneficiary of the global GLP-1 drug boom, with new peptide manufacturing contracts and ...
Aug 6 (Reuters) - India's Divi's Laboratories (DIVI.NS), opens new tab reported first-quarter profit below estimates on Wednesday, as manufacturers producing generic drugs continued to be negatively ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results